A5103093946- Treatment of Major Depression
- Neurological disorders and treatments
- Mental Health Research Topics
- Electroconvulsive Therapy Studies
- Tryptophan and brain disorders
- Attention Deficit Hyperactivity Disorder
- Pain Management and Treatment
- Vagus Nerve Stimulation Research
- Transcranial Magnetic Stimulation Studies
- Electrolyte and hormonal disorders
- Mental Health Treatment and Access
- Bipolar Disorder and Treatment
- Child and Adolescent Psychosocial and Emotional Development
- Hormonal Regulation and Hypertension
- Maternal Mental Health During Pregnancy and Postpartum
- Pharmacological Effects and Toxicity Studies
- Liver Disease and Transplantation
- Cardiac pacing and defibrillation studies
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Film in Education and Therapy
- Hallucinations in medical conditions
- Ureteral procedures and complications
- Liver Disease Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Functional Brain Connectivity Studies
Sheppard Pratt Health System
2007-2025
University of Maryland, Baltimore
2019-2024
Sheppard and Enoch Pratt Hospital
2018-2023
Towson University
2018
Belmont Hospital
1989
Article AbstractObjective: To evaluate the efficacy and safety of olanzapine, divalproex, placebo in a randomized, double-blind trial mild to moderate mania (DSM-IV-TR criteria). Method: The study was conducted from October 2004 December 2006. A total 521 patients private practices, hospitals, university clinics were randomly assigned olanzapine (5-20 mg/day), divalproex (500-2500 or for 3 weeks; those completing continued with 9-week extension. Efficacy (mean change Young Mania Rating Scale...
Major depressive disorder (MDD) is a mental health that can cause disability and functional impairment standard-of-care (SOC) antidepressant therapies (ADTs) take weeks to treat. Zuranolone neuroactive steroid positive allosteric modulator of synaptic extrasynaptic γ-aminobutyric acid (GABA) type A receptors approved as an oral, once-daily, 14-day treatment course in adults with postpartum depression under investigation MDD. The phase 3 CORAL Study (NCT04476030) evaluated the efficacy safety...
Background: Duloxetine and escitalopram were compared in an 8-month, randomized, double-blind, placebo-controlled trial adult outpatients meeting DSM‑IV criteria for major depressive disorder (MDD). The results regarding the primary objective of study (onset antidepressant action) have been previously published. current paper focuses on longer-term (8-month) comparisons efficacy safety between duloxetine escitalopram.Research design methods: Upon completion 8-week, fixed-dose,...
Objective: Characteristics of difficult-to-treat depression (DTD), including infrequent symptom remission and poor durability benefit, compel reconsideration the outcome metrics historically used to gauge effectiveness antidepressant interventions. Methods: Self-report clinician assessments severity were obtained regularly over a 2-year period in registry sample receiving treatment as usual (TAU), with or without vagus nerve stimulation (VNS). Alternative for characterizing change compared...
Abstract Background In difficult-to-treat depression (DTD) the outcome metrics historically used to evaluate treatment effectiveness may be suboptimal. Metrics based on remission status and single end-point (SEP) assessment problematic given infrequent symptom remission, temporal instability, poor durability of benefit in DTD. Methods Self-report clinician severity were regularly obtained over a 2-year period chronic highly treatment-resistant registry sample ( N = 406) receiving as usual,...
Objective: Zuranolone is a positive allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid (GABA) type A receptors neuroactive steroid approved in the United States as an oral, once-daily, 14-day treatment course for adults with postpartum depression under investigation major depressive disorder (MDD). Interim results from open-label, longitudinal, phase 3 SHORELINE Study (NCT03864614) that evaluated long-term safety efficacy zuranolone MDD are reported.Methods: This...
Objective: To describe the clinical characteristics of adolescents with antidepressant treatment-resistant major depressive disorder (MDD) and to examine utility Antidepressant Treatment Record (ATR) in categorizing treatment resistance this population. Methods: Adolescents MDD enrolled an interventional study underwent a baseline evaluation ATR, Children's Depression Rating Scale-Revised (CDRS-R), Clinical Global Impressions-Severity (CGI-S) scales. Demographic were examined regard...
Introduction Zuranolone (ZRN) is a positive allosteric modulator of both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors neuroactive steroid approved as an oral, once-daily, 14-day treatment course for adults with postpartum depression in the US under investigation major depressive disorder (MDD). The randomised, double-blind, placebo-controlled, Phase 3 CORAL Study assessed efficacy safety ZRN 50 mg vs placebo, each co-initiated open-label standard-of-care antidepressant...